Santhera Pharmaceuticals

Santhera Pharmaceuticals, headquartered in Switzerland, is a pharmaceutical company dedicated to the research and development of innovative medicines for patients suffering from mitochondrial disorders and rare neuromuscular and pulmonary diseases. The company primarily serves patients who have limited or no treatment options available, focusing on conditions such as Duchenne Muscular Dystrophy and other rare diseases.

Santhera operates in the biopharmaceutical market, leveraging its expertise in drug development to bring new therapies from the research phase through to commercialization. The company’s business model involves extensive research and clinical trials to ensure the efficacy and safety of its products, followed by regulatory approval and market launch. Revenue is generated through the sale of its proprietary medicines, as well as potential partnerships and licensing agreements with other pharmaceutical companies.

Santhera recently completed a capital increase to strengthen its financial position and support ongoing and future projects. The company is also actively engaged in collaborations, such as with ReveraGen, to advance the development and commercialization of promising treatments.

Keywords: neuromuscular diseases, pulmonary diseases, rare diseases, mitochondrial disorders, drug development, clinical trials, regulatory approval, biopharmaceutical, capital increase, partnerships.